Some of the companies operating in the Gastric Cancer Therapeutics Market in the current scenario are Pfizer, Eli Lilly, GlaxoSmithKline plc, Kuhnil Pharmaceutical/Daiichi Sankyo, BMS, Merck KGaA, AstraZeneca, Otsuka Holdings Co. Ltd., Sanofi, and F. Hoffmann-La Roche Ltd. Some of the other companies operating in the market are Ono Pharmaceutical/Bristol-Myers Squibb, Jiangsu HengRui Medicine, Gilead Bioscience, Celgene/Taiho, Boston Biomedical, and Merck.
Gastric cancer, also known as
stomach cancer, is a type of cancer that develops within the inside layer of
the stomach. Symptoms may include upper abdominal pain, yellowing of the skin,
heartburn, sudden weight loss, blood in the stool, loss of appetite, and
nausea, among others. This type of cancer may multiply to unaffected parts of
the body mainly to the lungs, liver, the lining of the abdomen, lymph nodes,
and bones. The key cause of gastric cancer is contagion by Helicobacter pylori.
This accounts for around 60% of the gastric cancer cases. Some types of H.
pylori comprise larger risks than the others. Some of the other causes include
smoking and eating pickled vegetables. Around 1 in 10 cases of gastric cancer
are inherited and 1% to 3% of the cases are due to hereditary syndromes such as
hereditary gastric cancer. Most cases of gastric cancers are gastric
carcinomas.
According to World Cancer Research
Fund International, 952,000 new cases of gastric cancer were diagnosed in 2012.
Gastric cancer was the fifth-most common type of cancer in the world. This
epidemic has forced researchers, doctors, and governments to adopt various
therapeutic treatments related to gastric cancer. An increase in investment by
the companies and regulations by the government encouraging research on the
same has provided significant momentum to the growth of the gastric cancer
therapeutics market. This trend is likely to persist throughout the forecast
period, since the number of cases of gastric cancer around the globe is rising
at an alarming rate.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/194
According to National Cancer Institute,
there were a projected 79,843 individuals with stomach cancer in the U.S.
alone, in 2013. According to the same report, gastric cancer represented a
whopping 1.6% of the new cancer cases reported in the U.S. According to the
National Cancer Institute, an estimated 26,370 new cases of the disease were
reported, leading to 10,730 deaths in the U.S. in 2016. Rising incidence of
stomach cancer in the U.S., positions it as a high growth market for gastric
cancer therapeutics.
Increasing prevalence of the
disease in the Asia to drive growth of overall gastric cancer therapeutics
market
Survival rate for stomach cancer
is greatly dependent upon the stage or phase of the disease during diagnosis.
The earlier the stage of the disease progression, the higher is the survival
rate. In Asia Pacific, the majority of the cases are detected at the later
stage of the disease and predominantly among the geriatric population. Growth
of the geriatric population in the region is leading to a proportional increase
in occurrence of gastric cancer. This factor, along with growing health
awareness leading to a rise in demand for early detection would fuel growth of
the gastric cancer therapeutics industry over the forecast period.
Presently, the products available
in the market constitutes of an extensive variety of treatment alternatives
such as angiogenesis inhibitors, new chemotherapies and HER2-targeted therapy.
However, demand for therapeutics that can take care of HER2-negative stomach
cancer patients is high. Nevertheless, the gastric cancer market is
experiencing a gradual change from generic treatment regimen to targeted
therapies. This will further enhance the growth of the global gastric cancer
therapeutics market.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/gastric-cancer-therapeutics-market-194
Key Developments
Key players in the market are
focused on launching new products to expand their product portfolio. For
instance, in April 2019, F. Hoffmann-La Roche AG launched VENTANA HER2 Dual ISH
DNA Probe Cocktail assay for the detection of the HER2 biomarker in breast and
gastric cancer.
Major market players are focused
on adopting collaboration strategies to develop novel therapies for gastric
cancer. For instance, in February 2019, GlaxoSmithKline plc. and Merck KGaA
entered into a global strategic alliance to jointly develop and commercialize
M7824, an investigational bifunctional fusion protein immunotherapy under
clinical development stage, for the treatment of human
papillomavirus-associated cancers, biliary tract cancer (BTC), and gastric
cancer.
Key market players are also
focused on gaining regulatory approvals to expand their product portfolio. Fro
instance, in August 2019, Taiho Pharmaceutical Co., Ltd. obtained additional
indication of unresectable advanced or recurrent gastric cancer that has
progressed after chemotherapy for its anticancer agent LONSURF, an oral
anticancer drug that uses the combination of trifluridine (antineoplastic
nucleoside analogue) and tipiracil (a thymidine phosphorylase inhibitor), from
the Japanese Ministry of Health, Labor and Welfare.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/194
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting services,
and competitive analysis through various recommendations related to emerging
market trends, technologies, and potential absolute dollar opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment